Showing results (81-90 of 905) with videos related to

Sort By:
Pageof 91
Journal of Cardiac Failure|June 10, 2006
Diuretic use, progressive heart failure, and death in patients in the DIG studyMichael Domanski, Xin Tian, Mark Haigney, et al.
Journal of Veterinary Internal Medicine|February 27, 2019
The renin-angiotensin-aldosterone system and its suppressionMarisa K Ames, Clarke E Atkins, Bertram Pitt
Future Cardiology|December 22, 2011
PEARL-HF: prevention of hyperkalemia in patients with heart failure using a novel polymeric potassium binder, RLY5016Jerry M Buysse, I-Zu Huang, Bertram Pitt
Circulation. Heart Failure|January 21, 2020
Mechanistic Effects of Spironolactone on Cardiovascular and Renal Biomarkers in Heart Failure With Preserved Ejection Fraction: A TOPCAT Biorepository StudyPeder L Myhre, Muthiah Vaduganathan, Eileen O'Meara, et al.
JACC. Heart Failure|April 1, 2017
Interaction Between Spironolactone and Natriuretic Peptides in Patients With Heart Failure and Preserved Ejection Fraction: From the TOPCAT TrialInder S Anand, Brian Claggett, Jiankang Liu, et al.
Hypertension (Dallas, Tex. : 1979)|August 25, 2020
Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart FailureChristopher Stuart Wilcox, Jeffrey Moore Testani, Bertram Pitt
European Heart Journal|June 7, 2013
The human coronary collateral circulation: development and clinical importanceChristian Seiler, Michael Stoller, Bertram Pitt, et al.
European Heart Journal|September 17, 2015
Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fractionScott D Solomon, Brian Claggett, Eldrin F Lewis, et al.
Lancet (London, England)|June 1, 2005
Heart failureJohn J V McMurray, Marc A Pfeffer
ESC Heart Failure|January 13, 2021
Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trialCorrado De Marco, Brian L Claggett, Simon de Denus, et al.
Pageof 91